Home > Insider Trading > Filing (0001127602-22-008274)

Filing Details

Accession Number:: 0001127602-22-008274
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2022-03-04 16:33:12
Reporting Period:: 2022-01-06

Accepted Time:: 2022-03-04 16:33:12
Original Submission Date:: 2022-01-06
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1082554	United Therapeutics Corp	UTHR	Pharmaceutical Preparations (2834)	521984749

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1231589	A Paul Mahon	C/O United Therapeutics Corporation 1040 Spring Street Silver Spring MD 20910	Evp & General Counsel	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-01-06	6,000	$111.00	42,369	No	4	M	Direct
Common Stock	Disposition	2022-01-06	320	$190.48	42,049	No	4	S	Direct
Common Stock	Disposition	2022-01-06	2,970	$192.32	39,079	No	4	S	Direct
Common Stock	Disposition	2022-01-06	2,710	$192.85	36,369	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Options	Disposition	2022-01-06	6,000	$0.00	6,000	$111.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,094	2019-03-15	2028-03-15	No	4	M	Direct

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	Stock Options	$111.00	2021-03-15	2028-03-15	81,458	81,458	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2028-03-15	81,458	81,458	Direct

Footnotes

This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person.
This acquisition of common stock was inadvertently omitted from Table I on the original filing due to administrative error, although the corresponding option exercise was included on Table II. As a result, three subsequent Form 4 filings also incorrectly understated the reporting person's common stock balance by 6,000 shares (filed on January 20, 2022, February 3, 2022, and February 17, 2022).
This transaction was executed in multiple trades at prices ranging from $190.32 to $190.74. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $191.65 to $192.64. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $192.65 to $193.28. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
The reporting person received two stock option grants, both with the same grant date and exercise price. Due to administrative error, previous option exercises occasionally were reported on Table II as having been drawn from the wrong tranche. This balance has been updated to correct these errors.